Selected Publications
2022
Prediction of Life-threatening and Disabling Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Versluis J, Pandey M, Flamand Y, Haydu JE, Belizaire R, Faber MG, Vedula RS, Charles A, Copson KM, Shimony S, Rozental A, Bendapudi P, Wolach O, Griffiths EA, Thompson JE, Stone RM, DeAngelo DJ, Neuberg D, Luskin MR, Wang ES, Lindsley RC.
Blood Adv. 2022 Jan 26:bloodadvances.2021006166. doi: 10.1182/bloodadvances.2021006166. PMID: 35081257.
2021
BCOR and BCORL1 mutations drive epigenetic reprogramming and oncogenic signaling by unlinking PRC1.1 from target genes
Schaefer EJ, Wang HC, Karp HQ, Meyer CA, Cejas P, Gearhart MD, Adelman ER, Fares I, Apffel A, Lim K, Xie Y, Gibson CJ, Schenone M, Murdock HM, Wang EZ, Gondek LP, Carroll MP, Vedula RS, Winer ES, Garcia JS, Stone RM, Luskin MR, Carr SA, Long HW, Bardwell VJ, Figueroa ME, Lindsley RC
Blood Cancer Discovery, 2021 Dec 17:bloodcandisc.0115.2021. doi: 10.1158/2643-3230.BCD-21-0115
Allelic Complexity of KMT2A Partial Tandem Duplications in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Tsai HK, Gibson CJ, Murdock HM, Davineni P, Harris MH, Wang ES, Gondek LP, Kim AS, Nardi V, Lindsley RC
medRxiv 2021.11.01.21265781; doi: https://doi.org/10.1101/2021.11.01.21265781
Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease.
Vedula RS, Cheng MP, Ronayne CE, Farmakiotis D, Ho VT, Koo S, Marty FM, Lindsley RC*, Bold TD*.
Blood Adv. 2021 Jan 12;5(1):54-60. doi: 10.1182/bloodadvances.2020002854. PMID: 33570623; PMCID: PMC7805332.
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
Haydu JE, Flamand Y, Vedula RS, Versluis J, Charles A, Copson KM, Stone RM, DeAngelo DJ, Neuberg D, Lindsley RC*, Luskin MR*.
Am J Hematol. 2021 Apr 10. doi: 10.1002/ajh.26188. Epub ahead of print. PMID: 33837971.
Prediction of Life-threatening and Disabling Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Versluis J, Pandey M, Flamand Y, Haydu JE, Belizaire R, Faber MG, Vedula RS, Charles A, Copson KM, Shimony S, Rozental A, Bendapudi P, Wolach O, Griffiths EA, Thompson JE, Stone RM, DeAngelo DJ, Neuberg D, Luskin MR, Wang ES, Lindsley RC.
Blood Adv. 2022 Jan 26:bloodadvances.2021006166. doi: 10.1182/bloodadvances.2021006166. PMID: 35081257.
2021
BCOR and BCORL1 mutations drive epigenetic reprogramming and oncogenic signaling by unlinking PRC1.1 from target genes
Schaefer EJ, Wang HC, Karp HQ, Meyer CA, Cejas P, Gearhart MD, Adelman ER, Fares I, Apffel A, Lim K, Xie Y, Gibson CJ, Schenone M, Murdock HM, Wang EZ, Gondek LP, Carroll MP, Vedula RS, Winer ES, Garcia JS, Stone RM, Luskin MR, Carr SA, Long HW, Bardwell VJ, Figueroa ME, Lindsley RC
Blood Cancer Discovery, 2021 Dec 17:bloodcandisc.0115.2021. doi: 10.1158/2643-3230.BCD-21-0115
Allelic Complexity of KMT2A Partial Tandem Duplications in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Tsai HK, Gibson CJ, Murdock HM, Davineni P, Harris MH, Wang ES, Gondek LP, Kim AS, Nardi V, Lindsley RC
medRxiv 2021.11.01.21265781; doi: https://doi.org/10.1101/2021.11.01.21265781
Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease.
Vedula RS, Cheng MP, Ronayne CE, Farmakiotis D, Ho VT, Koo S, Marty FM, Lindsley RC*, Bold TD*.
Blood Adv. 2021 Jan 12;5(1):54-60. doi: 10.1182/bloodadvances.2020002854. PMID: 33570623; PMCID: PMC7805332.
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
Haydu JE, Flamand Y, Vedula RS, Versluis J, Charles A, Copson KM, Stone RM, DeAngelo DJ, Neuberg D, Lindsley RC*, Luskin MR*.
Am J Hematol. 2021 Apr 10. doi: 10.1002/ajh.26188. Epub ahead of print. PMID: 33837971.
Selected Abstracts
Marlise R. Luskin, Angel M. Cronin, Kevin Copson, Wooram Jung, Martha Wadleigh, Daniel J. DeAngelo, David P. Steensma, Jane Driver, Andrew A. Lane, R. Coleman Lindsley, Gregory A. Abel; Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies. Blood 2017; 130 (Supplement 1): 4276. doi: https://doi.org/10.1182/blood.V130.Suppl_1.4276.4276
Rahul S. Vedula, Marlise R. Luskin, Kevin Copson, Priti Kumari, Anne Charles, Annette S. Kim, Elizabeth A Morgan, Gregory A. Abel, Richard M. Stone, Andrew A. Lane, R. Coleman Lindsley; Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities. Blood 2018; 132 (Supplement 1): 1819. doi: https://doi.org/10.1182/blood-2018-99-118746
Rahul S. Vedula, Marlise R. Luskin, Kevin Copson, Priti Kumari, Anne Charles, Annette S. Kim, Elizabeth A Morgan, Gregory A. Abel, Richard M. Stone, Andrew A. Lane, R. Coleman Lindsley; Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities. Blood 2018; 132 (Supplement 1): 1819. doi: https://doi.org/10.1182/blood-2018-99-118746